Melanotan II: what the alpha-MSH analog actually does, and what it doesn't

Melanotan II, MT-II in the literature, is a synthetic cyclic heptapeptide built off the structure of alpha-melanocyte-stimulating hormone, the body's own pigmentation signal. The Arizona team modified the linear α-MSH sequence by substituting key residues and cyclizing the molecule with a lactam bridge. The full chemical name is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ ^[2].

That cyclization matters. Linear peptides get chewed apart by enzymes within minutes. Cyclic ones don't. MT-II's loop structure makes it considerably more potent and more stable than its parent hormone, which is why a peptide originally proposed as a topical agent could be made to work as a subcutaneous injection.

The key pharmacophore, the part that actually docks into the receptor, is the four-residue sequence His-Phe-Arg-Trp ^[3]. That HFRW motif is shared across the melanocortin family and explains why MT-II hits not one receptor but four.

There are five melanocortin receptors in humans, designated MC1R through MC5R. They're all G-protein coupled receptors in the rhodopsin-like family A class. Agonist binding raises intracellular cAMP, which then drives whatever downstream program a given cell type runs.

MT-II is a non-selective agonist. It activates MC1R, MC3R, MC4R, and MC5R, and largely ignores MC2R ^[4], which is the ACTH receptor in the adrenal cortex and a different beast.

This is the single most important thing to understand about the drug. It's not a tanning peptide that happens to have side effects. It's a four-receptor agonist whose downstream effects are determined by which tissue you're talking about.

MC1R sits on peripheral melanocytes. Activate it and the cell turns on eumelanin synthesis, the darker pigment that mediates the tanning response. MC1R also has anti-inflammatory effects through NF-κB modulation.

MC3R lives in the hypothalamus and on immune cells. It participates in energy homeostasis and dampens inflammation through the cholinergic anti-inflammatory pathway.

MC4R is the central one, literally. It's expressed in the hypothalamus and brainstem. It suppresses appetite, ramps up sympathetic nervous system outflow, and drives the pro-erectile pathway that takes MT-II out of the realm of cosmetic peptide and into the realm of cardiovascular drug.

MC5R is found on exocrine glands and various peripheral tissues; its role in MT-II's clinical picture is less well-characterized.

So when someone injects MT-II to darken their skin, the MC1R activation produces the wanted effect. The MC4R activation produces nausea, elevated blood pressure, sweating, and a spontaneous erection. Same molecule. Different receptors. Different tissues.

Melanogenesis driven by MT-II proceeds independently of UV exposure. The drug bypasses the normal physiological cascade of UV damage to keratinocytes, p53 induction, α-MSH release, and MC1R activation, and just walks straight up to the melanocyte and turns the switch.

In the original 1996 Phase I trial, three healthy male subjects received five subcutaneous doses on an every-other-day schedule ^[5]. Tanning was observed. So was nausea, in every subject, at every dose level. And one of the volunteers reported a spontaneous, unmedicated erection.

The pigmentation effect is real. The mechanism is established. What was never established, in any controlled trial, is whether the tanning effect can be obtained without the receptor activation everywhere else.

The pro-erectile effect of MT-II runs through MC4R in the central nervous system, not through the peripheral nitric-oxide/cGMP pathway that PDE5 inhibitors like sildenafil target. That's a meaningful pharmacological distinction. It means the erections MT-II produces are not response-dependent in the way Viagra-mediated erections are; they happen because a central melanocortin signal is firing, with or without sexual stimulus.

This is also the link to bremelanotide (PT-141), sold as Vyleesi. Bremelanotide is a deaminated acid derivative of MT-II ^[6] and a likely metabolite. It retains MC1R, MC3R, and MC4R activity, lost in regulatory translation as MT-II became gray-market and bremelanotide became prescription. The FDA approved bremelanotide in June 2019 (NDA 210557) for hypoactive sexual desire disorder in premenopausal women ^[7].

The same receptor pharmacology, in other words, produced one approved drug and one underground one. The difference is what the sponsors did with it, and what the molecule does at receptors beyond MC4R.

Activation of MC4R in the hypothalamus suppresses food intake. This is well-established melanocortin physiology and is why MC4R mutations are one of the most common monogenic causes of human obesity. MT-II reliably produces appetite suppression in users, sometimes large.

It hasn't been developed for that indication, for an obvious reason. The same MC4R activation that suppresses appetite also drives sympathetic outflow, with heart rate and blood pressure up, and pharmaceutical developers chasing the obesity market have favored more selective approaches. Setmelanotide, for instance, is an MC4R-targeted agonist approved in 2020 for rare genetic obesity syndromes ^[8], designed specifically to capture the metabolic effect without the worst of the cardiovascular activation.

MT-II is the opposite of selective. Its effect on body weight is real but comes bundled.

Here's where the asymmetry between online discussion of MT-II and the actual evidence base becomes hardest to ignore.

There's exactly one published Phase I human trial of Melanotan II. Three subjects. 1996. No control arm. No Phase 2 trial has ever been completed. No Phase 3 trial has ever been started. The drug has never been tested in women, never been tested in anyone over 50 in a controlled setting, never been tested for cardiovascular safety in a powered way, never been tested for cancer outcomes at all.

Everything else in the human literature is case reports.

That's not a rhetorical flourish. It's the literal state of the evidence: one tiny dose-finding study published in Life Sciences in 1996 ^[9], followed by three decades of dermatologists, urologists, and emergency physicians writing up what happens when people inject MT-II in their kitchens.

The animal record is more developed. Mouse work has shown MC4R-mediated reversal of social deficits in a maternal-immune-activation autism model. Zebrafish work has shown MT-II can reverse high-fat-diet-induced cognitive deficits. Medicinal chemistry groups have used MT-II as a scaffold to design more receptor-selective analogs. All interesting. None translatable to human safety claims without trials that don't exist.

The predictable side effects map onto the receptor pharmacology directly. Nausea is universal. In the original trial, every subject experienced it at every dose, and a systematic review of medical-intervention cases found nausea in a large majority of participants. Facial flushing, fatigue, sweating, dizziness, appetite suppression, and behavioral changes including agitation are all common.

Then there's the serious column.

Priapism, erection lasting more than four hours, a urological emergency, has been documented in multiple peer-reviewed case reports. Dreyer and colleagues described a patient who received cavernosal aspiration, irrigation, and intracavernosal phenylephrine and had not recovered erectile function at follow-up. A second case required a Winter's shunt after phenylephrine failed ^[10]. Systematic reviews of adverse event reporting have noted that priapism, when it occurs, frequently requires medical intervention, though the true incidence remains difficult to establish given inconsistent reporting across the literature.

Rhabdomyolysis. Nelson and colleagues reported a 39-year-old man who developed creatine kinase of 17,773 IU/L, a heart rate of 146, and acute kidney injury after a single 6 mg subcutaneous injection ^[11]. CK that high is muscle breakdown on a scale that backs into kidney failure. Some reports have linked rhabdomyolysis to a notable share of intervention cases.

Hypertensive crisis. A majority of the medical-intervention cases in the same review had systolic pressures above 180 mmHg.

Renal infarction. Peters and colleagues reported a previously normotensive patient who developed right-sided renal infarction after six months of MT-II use ^[12]. The proposed mechanism involves both thrombotic effects and possible direct renal toxicity.

These are not in-aggregate population estimates. The denominator is unknown and the reporting is heavily biased toward people who actually presented to hospitals. But they're real events in real patients, replicated independently across multiple countries, and the receptor pharmacology gives every one of them a plausible mechanism.

The most contested adverse-event signal, and the one that matters most for long-term risk, involves pigmented lesions.

Dermatology has been publishing on this since at least 2009. Early case reports documented transformation of preexisting nevi after Melanotan use, with histopathology showing severely dysplastic melanocytic nevi. Cardones and Grichnik described eruption of new atypical nevi in a patient with a personal history of dysplastic nevi and melanoma. Cousen and colleagues described eruptive nevi in a young sunbed user. Paurobally and colleagues reported transformation of an existing nevus to a thin melanoma shortly after melanotan injections. A Spanish case report described a young man who developed numerous new melanocytic nevi after an MT-II course, with three lesions showing severe dysplasia on biopsy.

Reviews of the available literature have identified a small number of melanoma cases temporally associated with MT-II or Melanotan I, though the case counts vary depending on which studies are included and how cases are defined. The 2017 Habbema review reached similar conclusions ^[13].

Causation has not been established. Users typically have multiple concurrent melanoma risk factors, including fair skin, sunbed use, and family history. MT-II is the variable they added on top, and disentangling its independent contribution from a case series is statistically impossible.

What is established is temporal association across multiple independent reports, in multiple countries, with biological plausibility from MC1R-driven melanogenesis acting on melanocytes that may already harbor mutations. Dermatology consensus, where it exists, treats this as a real signal that demands mole surveillance in anyone who has used the drug, even retrospectively.

The honest read is that we don't know the lifetime melanoma risk attributable to MT-II. We know there's smoke, and we know the chemistry suggests there could be fire, and we know nobody has run, or will run, the prospective cohort study that would settle it.

Melanotan II is not approved by the FDA for any indication. It has never been approved by the EMA, the MHRA, the TGA, or any other major regulator. It is also not eligible for compounding: a bulk substance qualifies under Section 503A only if it appears on FDA's 503A bulks list, carries a USP or NF monograph, or is a component of an approved drug, and melanotan II is none of the three ^[14].

The 2026 reclassification news is often reported as if it changed that. It did not. FDA placed melanotan II in Category 2 of its interim 503A policy in September 2023 — the bucket for substances the agency considers to present significant safety risks. In April 2026 it removed melanotan II and eleven other peptides from Category 2, not because the safety questions were resolved but because the original nominators withdrew their submissions.

The effect was to lift a stated prohibition without granting permission: neither banned nor allowed. Seven of those twelve went before the Pharmacy Compounding Advisory Committee on July 23-24, 2026, and melanotan II was not one of them — its own review is scheduled to follow before February 2027, alongside GHK-Cu, cathelicidin (LL-37), dihexa acetate and PEG-MGF. Committee recommendations are non-binding in any case, and nothing changes in law until FDA completes rulemaking, which has not started. Our report on the July meeting has the record.

In the United States, MT-II sold for human use is, by definition, an unapproved new drug. The FDA has issued public warnings on multiple occasions citing serious adverse events and lack of safety data. Sales typically rebrand the molecule as a "research chemical," a regulatory dodge that doesn't change what the drug does in tissue.

International enforcement varies. UK and Irish authorities have been particularly active given the prevalence of use among sunbed users; a 2021 qualitative study analyzed 623 forum discussions from January 2016 through October 2017 ^[15] and found extensive evidence of misinformation, dosing errors, and product preparation problems.

Product quality is its own category of risk. Independent analyses of online-purchased alpha-MSH analog products have found frequent contamination and outright compound misidentification. You don't always get MT-II when you buy MT-II. Sometimes you get something else. Sometimes you get MT-II plus something else.

The melanocortin space contains three named molecules that get conflated constantly. They're not the same.

Melanotan I, now called afamelanotide, sold as Scenesse. A linear α-MSH analog, MC1R-selective (or close enough that the other receptor activity doesn't dominate the clinical picture). Approved by the EMA in 2014 and by the FDA in October 2019 (NDA 210797) for erythropoietic protoporphyria ^[16], a rare metabolic disorder in which patients experience severe phototoxic reactions to sunlight. Administered as a pharmaceutical-grade subcutaneous implant by trained physicians.

Melanotan II. The cyclic, non-selective, four-receptor peptide this guide is about. Never approved anywhere.

Bremelanotide, sold as Vyleesi. A deaminated derivative of MT-II, still active at MC1R, MC3R, and MC4R. FDA-approved in June 2019 (NDA 210557) for hypoactive sexual desire disorder in premenopausal women, administered as a single-use subcutaneous autoinjector before anticipated sexual activity.

The afamelanotide approval is instructive because it shows what melanocortin-pathway approval actually requires.

The clinical condition, erythropoietic protoporphyria, is a real, identifiable disease with a defined patient population, validated endpoints (phototoxic-reaction-free time outdoors), and an unmet medical need. The sponsor, Clinuvel Pharmaceuticals, ran multi-year clinical trials, established a manufacturing pathway, designed a controlled-release implant to avoid systemic peaks, and built a Risk Evaluation and Mitigation Strategy program that includes mandatory provider training and periodic skin examinations for melanoma surveillance.

MT-II had none of this. It had a Phase I trial in three men, a tanning indication that the FDA would never consider serious enough to justify systemic melanocortin activation, and a non-selective receptor profile that virtually guaranteed an unfavorable risk-benefit calculation for cosmetic use.

The lesson isn't that MT-II is uniquely dangerous and afamelanotide is uniquely safe. Afamelanotide carries its own melanoma surveillance requirement in its label. The lesson is that one team developed their molecule, and the other team's molecule got developed by the internet.

The FDA Adverse Event Reporting System contains reports for MT-II. Chronic kidney disease shows up hundreds of times. "Drug ineffective" shows up hundreds of times.

These numbers need a heavy interpretive hand. FAERS captures whatever gets reported, with no denominator and massive underreporting. For an unapproved drug used outside any medical system, the reporting bias runs in both directions: most adverse events never get reported, but when severe ones do, they may cluster in ways that overstate frequency. Treat FAERS as a hypothesis-generating signal, not a rate.

The serious academic interest in MT-II has come from three quarters. The original Arizona group around Mac Hadley and Robert Dorr, who designed it ^[17]. Medicinal chemists who use the scaffold to build more selective analogs; Tomassi and colleagues published novel hMC1R-selective derivatives in J Med Chem in 2022 ^[18]. And dermatology and emergency medicine groups in the UK, Ireland, Australia, and Northern Europe, who have done most of the post-marketing pharmacovigilance the formal system never did.

What remains genuinely unknown is large. The long-term cardiovascular risk in chronic users. The lifetime melanoma risk attributable to the drug independent of co-exposures. The minimum effective dose for pigmentation alone. Whether selective MC1R agonism could deliver tanning without the central effects; afamelanotide is the closest thing we have to an answer, but it's not freely available outside its EPP indication. The pharmacokinetics in humans in any rigorous sense.

What the data support: that MT-II reliably activates four melanocortin receptors; that pigmentation, appetite suppression, and pro-erectile effects are mechanistically well-explained; that nausea is universal; that priapism, rhabdomyolysis, hypertensive crisis, and renal infarction have all been documented in independent case reports; that a temporal association with dysplastic nevi and melanoma exists across multiple countries and patient series.

What the data don't support: any claim about long-term safety; any controlled-trial dose recommendation; any quantification of the melanoma signal; any meaningful distinction between MT-II as "research chemical" and MT-II as drug.

What's striking, sitting with the literature, is the asymmetry. The molecule has been in widespread underground human use for roughly two decades, and the body of high-quality human data remains three subjects in one trial from 1996, plus case reports written by clinicians cleaning up after the fact. That's not a regulatory accident. That's what happens when a compound skips the development process the modern drug-safety system is built around.